Companies
Cybin, now Helus Pharma
Summary
Cybin, now Helus Pharma, is a biopharmaceutical company developing deuterated serotonergic compounds, with HLP003/CYB003 now positioned inside a Phase 3 depression program.
Why it matters
Cybin’s shift into Helus Pharma is a continuity problem and a trust problem at the same time: the name changed, but the clinical program, investor record, and trial references still need to stay legible under the old route and story footprint.
Research notes
Context, reporting, and structured background for this dossier.
Cybin said in January 2025 that it would rebrand as Helus Pharma and shift its U.S. listing to Nasdaq. That means the company’s official public identity changed, but the older Cybin name still matters for continuity across reporting, stock-market references, and trial-program history.
Continuity and naming
The rebrand is not just cosmetic. It changes the official site, investor-relations surface, and how newer program materials are titled. This page keeps the legacy cybin route while making the current Helus identity explicit, so readers can connect the older company record to the current one without breaking continuity.
Clinical program
Helus’s own program materials now describe HLP003, formerly referred to as CYB003, as a deuterated novel serotonergic agonist with FDA Breakthrough Therapy Designation for adjunctive treatment of major depressive disorder. The company’s clinical-trials page explicitly notes that HLP003 was formerly CYB003, which helps close the naming gap between older Cybin-era reporting and newer Helus-era program language.
The Phase 3 PARADIGM program, outlined in Helus investor materials, organizes the depression effort into APPROACH, EMBRACE, and EXTEND. Public registry coverage through NCT06564818 helps anchor the program in a checkable trial record rather than only investor copy.
Why this page matters
Cybin/Helus remains one of the more advanced psychedelic-compound developers and one of the clearest examples of how naming continuity, investor communications, and clinical-trial status can drift apart if the dossier is not maintained carefully. The route stays cybin, but the live company and program language now belong to Helus.
Citations and source links
Source material used to ground or extend this dossier.
- Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq in Early January
Public press-release page documenting the company’s rebrand from Cybin to Helus Pharma.
- Cybin Inc. Completes Rebrand to Helus and Share Consolidation
Follow-on public release confirming the transition from the Cybin name into Helus branding.
- Cybin Initiates PARADIGM Phase 3 Program for CYB003 in MDD
Company release outlining the Phase 3 APPROACH, EMBRACE, and EXTEND structure around CYB003.
- NCT06564818
Registry record for a CYB003 study in major depressive disorder.
Related entities
Other dossiers that help connect this page to the wider reporting record.
- Psilocybin
Psilocybin is the prodrug active compound in psilocybin mushrooms, converted in the body to psilocin. Under investigation for treatment-resistant depression, PTSD, OCD, alcohol use…
- Treatment-Resistant Depression (TRD)
Treatment-resistant depression is generally defined as depression that has failed to respond to at least two adequate antidepressant trials. Affects roughly 30% of people with majo…
- FDA
The U.S. Food and Drug Administration is the gatekeeper for psychedelic drug development in the United States, from IND clearance through advisory committee review and any eventual approval or rejection.